Prospective study of bevacizumab plus temozolomide in patients with advanced neuroendocrine tumors (Q33402226)

26 July 2017

Prospective study of bevacizumab plus temozolomide in patients with advanced neuroendocrine tumors (English)

1 reference

26 July 2017

1 reference

0 references

Rebecca Miksad

6

0 references

Jeffrey A Meyerhardt

9

object named as

Jeffrey A Meyerhardt

1 reference

26 July 2017

11

Charles S Fuchs

1 reference

26 July 2017

Jennifer A Chan

1

1 reference

26 July 2017

Keith Stuart

2

1 reference

26 July 2017

Craig C Earle

3

1 reference

26 July 2017

Jeffrey W Clark

4

1 reference

26 July 2017

Pankaj Bhargava

5

1 reference

26 July 2017

Lawrence Blaszkowsky

7

1 reference

26 July 2017

Peter C Enzinger

8

1 reference

26 July 2017

Hui Zheng

10

1 reference

26 July 2017

Matthew H Kulke

12

1 reference

26 July 2017

language of work or name

English

0 references

publication date

9 July 2012

1 reference

Journal of Clinical Oncology

26 July 2017

1 reference

26 July 2017

30

1 reference

26 July 2017

2963-2968

1 reference

26 July 2017

24

1 reference

Everolimus for advanced pancreatic neuroendocrine tumors.

26 July 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4874232

Sunitinib malate for the treatment of pancreatic neuroendocrine tumors

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4874232

A prospective phase II study of 2-methoxyestradiol administered in combination with bevacizumab in patients with metastatic carcinoid tumors

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4874232

First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4874232

O6-methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumors

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4874232

Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4874232

Combination chemotherapy trials in metastatic carcinoid tumor and the malignant carcinoid syndrome

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4874232

Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4874232

Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4874232

Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4874232

Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4874232

Phase II/III study of doxorubicin with fluorouracil compared with streptozocin with fluorouracil or dacarbazine in the treatment of advanced carcinoid tumors: Eastern Cooperative Oncology Group Study E1281.

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4874232

Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4874232

Phase II trial of dacarbazine (DTIC) in advanced pancreatic islet cell carcinoma. Study of the Eastern Cooperative Oncology Group-E6282.

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4874232

First-line temozolomide combined with bevacizumab in metastatic melanoma: a multicentre phase II trial (SAKK 50/07)

31 October 2018

1 reference

12 December 2020

Streptozocin–Doxorubicin, Streptozocin–Fluorouracil, or Chlorozotocin in the Treatment of Advanced Islet-Cell Carcinoma

1 reference

12 December 2020

Streptozocin plus fluorouracil versus doxorubicin therapy for metastatic carcinoid tumor

1 reference

12 December 2020

Phase II trials in journal of clinical oncology

1 reference

12 December 2020

Identifiers

DOI

10.1200/JCO.2011.40.3147

1 reference

26 July 2017

1 reference

26 July 2017

1 reference